HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kezuka, T. Articles by Streilein, J. W. Search for Related Content PubMed PubMed Citation Articles by Kezuka, T. Articles by Streilein, J. W.

In Vitro Generation of Regulatory CD8⁺ T Cells Similar to those Found in Mice with Anterior Chamber–Associated Immune Deviation

From the Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
PURPOSE. When injected intravenously into naïve mice, peritoneal exudate cells (PECs) incubated with ovalbumin (OVA) in the presence of transforming growth factor (TGF)-ß2 induce immune deviation similar to that evoked by injection of OVA into the anterior chamber of the eye. Intraocular antigen injection elicits two distinct populations of regulatory T cells that impair delayed hypersensitivity (DH) by two different mechanisms: a CD4⁺ T cell that suppresses the induction of DH (afferent) and a CD8⁺ T cell that inhibits DH expression. In an effort to understand the origin and mechanism of action of these regulatory cells, CD8⁺ T cells from OVA-specific T cell receptor (Tcr) transgenic mice (OT-1) were used.

METHODS. CD8⁺ T cells were harvested from Tcr transgenic OT-I mice whose Tcr recognize an OVA peptide in the context of the class I major histocompatibility complex molecule K^b. These cells were stimulated in vitro with OVA-pulsed PECs exposed (or not) to TGF-ß2, then analyzed for their capacity to proliferate, to secrete various cytokines, to lyse OVA-expressing target cells, and to regulate bystander T cells in vitro and in vivo.

RESULTS. When OVA-pulsed PECs were used in vitro as stimulators, responding OT-I T cells proliferated and preferentially secreted interferon (IFN)-, interleukin (IL)-2, and tumor necrosis factor (TNF)-, rather than IL-4 and IL-10. When the stimulator PECs were pretreated with TGF-ß2 and then pulsed with OVA, responding OT-I T cells proliferated even more swiftly, but they secreted significantly less IFN-, IL-2, and TNF-, and no IL-4 or IL-10. OT-I T cells, which constitutively display cytotoxicity toward OVA-expressing target cells, lost this activity when stimulated with OVA-pulsed, TGF-ß2–pretreated PECs. Moreover, OT-I T cells stimulated in this manner displayed the capacity to inhibit proliferation of OVA-primed T cells exposed to OVA in vitro and to suppress in vivo the expression of OVA-triggered DH.

CONCLUSIONS. OVA-pulsed PECs, pretreated with TGF-ß2, coerce naïve OVA-specific CD8⁺ T cells to become efferent regulators of DH similar to the regulatory T cells evoked by intraocular injection of OVA.

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Intraocular injection of exogenous antigens induces an Ag-specific impairment of systemic delayed hypersensitivity (DH). A wide range of antigens (including soluble proteins, tumor-associated, viral, and minor and major histocompatibility complex Ag) can induce this response, termed anterior chamber–associated immune deviation (ACAID).^{1 2 3 4} In mice in whom ACAID has been induced, two functionally distinct populations of regulatory cells have been described that suppress DH.⁵ One population of T cells is CD4⁺, which prevents in normal mice the induction of immunity leading to the generation of DH effectors (i.e.,. afferent regulators). Another population of regulatory T cells is CD8⁺, which inhibits the expression of DH in vivo (i.e., efferent regulators). To understand the cellular and molecular bases of ACAID, we have given the highest priority to generating, isolating, and studying these afferent and efferent regulatory cells.

To the present, attempts to harvest such cells in sufficient purity and quantity from spleens of mice with ACAID have failed. As an alternative approach, we have attempted to generate candidate regulatory cells in vitro by stimulating antigen-specific Tcr transgenic T cells with antigen-presenting cells pretreated with transforming growth factor (TGF)-ß2. It is now well established that peritoneal exudate cells (PECs) treated in vitro with TGF-ß2 acquire ACAID-inducing properties.⁶ We have recently determined that naïve CD4⁺ ovalbumin (OVA)-specific T cells from DO11.10 Tcr transgenic mice that were exposed to OVA-pulsed, TGF-ß2–pretreated PECs acquired the ability to suppress both induction and expression of DH in normal BALB/c mice.⁷

In the present study, we examined the functional properties of CD8⁺, OVA-specific T cells from OT-I mice after in vitro stimulation with OVA-pulsed, TGF-ß2–treated PECs. Our results indicate that OT-I T cells activated in this manner underwent proliferation but lost their cytotoxic capabilities. Moreover, the cells acquired the capacity to inhibit OVA-specific T cell proliferation in vitro and to suppress the expression of OVA-specific DH in vivo.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Mice
Female C57BL/6 (B6) mice, between 6 and 8 weeks of age, were purchased from Taconic Farms (Germantown, NY). These mice were used as a source of PECs. OT-I Tcr transgenic mice (C57BL/6 background) were maintained in our colony (original parents were a kind gift of Michael Bevan, University of Washington, Seattle, WA). All animals were treated according to the ARVO Statement on the Use of Animals in Ophthalmic and Vision Research. T cells from these mice recognize a peptide (residues 257–264) derived from OVA presented in the context of K^b.⁸ OT-I mice were used as the source of T cells, and as experimental subjects for in vivo studies of the expression of DH. OVA-specific Tcr transgenic T cells in OT-I mice were identified by surface flow cytometry for the expression of CD8 and V_ß5. In general, 17% to 40% of CD3⁺ T cells in lymphoid cell suspensions expressed CD8 and V_ß5.

Culture Medium
Serum-free medium was used for all cell cultures.⁹ This medium was composed of RPMI 1640, 10 mM HEPES, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin (all from Biowhitaker, Walksville, MD), 1 x 10^-5 M 2-ME (Sigma Chemical, St. Louis, MO), supplemented with 0.1% bovine serum albumin (Sigma Chemical), ITS⁺ culture supplement [1 µg/ml iron-free transferrin, 10 ng/ml linoleic acid, 0.3 ng/ml Na₂Se, and 0.2 µg/ml Fe(NO₃)₃; Collaborative Biochemical Products, Bedford, MA].

Reagents
Porcine TGF-ß2, anti–TGF-ß2 neutralizing antibody, and nonspecific goat antibody were purchased from R&D Systems (Minneapolis, MN). OVA and human serum albumin (HSA) were obtained from Sigma.

Preparation of Pure OT-I T Cells
Spleens were removed from OT-I mice and pressed through nylon mesh to produce a single-cell suspension. Red blood cells were lysed with Tris–NH₄Cl. The remaining cells were washed three times with RPMI 1640 and passed through T cell enrichment columns (R&D Systems). The resultant cell suspension contained >98% CD3⁺ cells.

Preparation of PECs Pretreated with TGF-ß2
PECs were harvested from normal C57BL/6 mice that received 2.5 ml of thioglycolate (Sigma) intraperitoneally 3 days earlier. As described previously,¹⁰ the cells were washed and resuspended, placed in 24- (1 x 10⁶/well) or 96-well (1 x 10⁵/well) culture plates, and treated with or without 5 ng/ml of porcine TGF-ß2 in serum-free medium at 37°C in an atmosphere of 5% CO₂. After overnight culture, plates were washed three times with culture medium to remove TGF-ß2 and nonadherent cells. Adherent cells were retained in the wells for use in all subsequent experiments. More than 90% of these adherent cells were F4/80⁺ macrophages.

Cytokine Assays
To assay for content of interferon (IFN)-, interleukin (IL)-2, IL-4, IL-10, tumor necrosis factor (TNF)-, and TGF-ß2, OT-I T cells (2 x 10⁴/well) were added to 96-well plates containing TGF-ß2–pretreated (or not) PECs (1 x 10⁵/well) and cultured with or without various concentrations of naive OVA in serum-free medium for 24 hours. In some experiments, irradiated (2000 R) OT-I T cells (2 x 10⁴/well) first cultured with OVA-pulsed, TGF-ß2–pretreated (or not) PECs were then cocultured in 96-well plates for 24, 48, and 72 hours with or without naive OVA- or HSA-pulsed PECs, and with T cells from C57BL/6 mice primed in vivo to OVA or HSA. Primed responder T cells were obtained as splenocytes from normal B6 mice primed 7 days previously with OVA or HSA plus complete Freund’s adjuvant. At each time point, supernatants were collected and analyzed by quantitative capture enzyme-linked immunosorbent assay (ELISA), according to the manufacturer’s instructions (PharMingen, San Diego, CA). Rat monoclonal antibodies (mAbs) to mouse cytokine IFN- (R4-6A2), IL-2 (JES6-1A12), IL-4 (BVD4-1D11), IL-10 (JES5-2A5), and TNF- (G281-2626) were purchased from PharMingen and used as coating Abs. Biotinylated rat mAbs to mouse cytokines IFN- (XMG1.2), IL-2 (JES6-5H4), IL-4 (BVD6-24G2), IL-10 (SXC-1), and TNF- (MP6-XT3; PharMingen) were used as detecting Abs. TGF-ß2 was quantified by ELISA kit (Promega, Madison, WI). For this ELISA to measure total TGF-ß2, supernatants were first treated with 1N HCl at a dilution of 1/10 for 1 hour at room temperature, then neutralized with a mixture of 1N NaOH/1N HEPES at a dilution of 1/5.

Proliferation Assay of T Cells Activated In Vitro
OT-I T cells were added (2 x 10⁴/well) to 96-well plates containing PECs (1 x 10⁵/well) pretreated (or not) with 5 ng/ml of TGF-ß2, and cultured with or without various concentrations of naive OVA in serum-free medium for 24 to 96 hours at 37°C in an atmosphere of 5% CO_2. In some experiments, X-irradiated (2000 R) OT-I T cells (2 x 10⁴/well), first cultured with OVA-pulsed, TGF-ß2–pretreated (or not) PECs, were then cocultured in 96-well plates with or without OVA- or HSA-pulsed PECs and T cells from C57BL/6 mice primed in vivo to OVA or HSA. The cultures were sustained for 24, 48, 72, or 96 hours, pulsed with 0.5 µCi [³H]-thymidine 8 hours before termination, and then harvested onto glass filters using an automated cell harvester (Tomtec, Orange, CT). Radioactivity was assessed by liquid scintillation spectrometry, and the amount expressed as counts per minute.

Assay for Cytotoxic Activity
To generate cytotoxic T lymphocytes (CTL), T cells (5 x 10⁵/well) taken from OT-I mice were stimulated with TGF-ß2 (5 ng/ml) pretreated (or not), OVA (400 µg/ml)-pulsed (or not) PECs (1 x 10⁶) for 0, 24, 48, or 96 hours in 24-well plates in serum-free medium. These cells were then washed three times and prepared as effector cells. EG.7 cells (EL4 cells transfected with the OVA gene,¹¹ a kind gift of Michael Bevan, University of Washington, Seattle, WA) were labeled with [⁵¹Cr]sodium chromate in serum-free medium for 1.5 hour at 37°C. The cells were washed three times, and 10⁴ cells were transferred to each well of a 96-well plate. Effector cells were added to these wells at E:T cell ratios ranging from 50:1 to 3:1 and incubated at 37°C in CO₂ in serum-free medium. After 4 hours, the plate was centrifuged, and 25 µl of supernatant was removed and counted. Results are expressed as the percent lysis as a function of the E:T cell ratio. The percent lysis = (test ⁵¹Cr released - spontaneous ⁵¹Cr released)/(maximum ⁵¹Cr released - spontaneous ⁵¹Cr released) x 100. Spontaneous ⁵¹Cr release was determined using ⁵¹Cr-labeled targets in the absence of effectors and maximum ⁵¹Cr release after treatment of ⁵¹Cr-labeled targets with 5N HCl.

Local Adoptive Transfer Assay of DH
This assay, as described previously, was used to detect the capacity of in vitro–activated OT-I T cells to suppress the expression of DH in vivo.¹² Briefly, OT-I T cells (5 x 10⁵) were cultured in 24-well plates containing TGF-ß2–treated, or –untreated, PECs and 400 µg/ml OVA. After 72 hours, nonadherent OT-I cells were harvested, washed three times, and exposed to X-irradiation (2000 R). These cells (as regulators) were added (1 x 10⁵/inoculum) to suspensions of OVA-pulsed PECs (as stimulators, 5 x 10⁵/inoculum) and responder T cells (5 x 10⁵/inoculum). Responder T cells were obtained as splenocytes from normal C57BL/6 mice primed 7 days previously with OVA plus complete Freund’s adjuvant (CFA). The mixture of responders, stimulators, and regulators was injected (10 µl/injection) into the ear pinnae of naive B6 mice. Ear swelling responses were assessed with an engineer’s micrometer (Mitsutoyo; MTI Corporation, Paramus, NJ) at 24 and 48 hours. In some experiments, neutralizing anti–TGF-ß2 antibodies or nonspecific goat antibodies (100 µg/mouse) were mixed with the cells and injected into ear pinnae.

Statistical Analyses
Results of experiments were analyzed by ANOVA and Scheffé test. Mean values were considered to be significantly different when P < 0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Capacity of OVA-Pulsed, TGF-ß2–Treated Antigen-Presenting Cells to Activate CD8⁺ T Cells from Tcr Transgenic OT-I Mice
Our first goal was to determine whether OT-I T cells, which are OVA-specific and restricted to H-2K^b, were capable of being activated in vitro after exposure to PECs that were treated with TGF-ß2 and pulsed with OVA. Accordingly, PECs were obtained from C57BL/6 donors and cultured with or without 5 ng/ml TGF-ß2 and various concentrations of OVA. After overnight culture, the cells were washed to remove TGF-ß2, OVA, and nonadherent cells, and then cocultured with naïve OT-I T cells. Two types of experimental assays were then performed: proliferation and cytokine content of supernatants. For assessment of T-cell proliferation, [³H]-thymidine was added and individual cultures were halted at 24, 48, 72, and 96 hours. Radioisotope incorporation was then determined. The results of a representative experiment are presented in Figure 1 . As expected, OT-I T cells that had been stimulated with OVA-pulsed, TGF-ß–untreated PECs began to proliferate at 72 hours, peaking at 96 hours. Similarly, OT-I T cells stimulated with OVA-pulsed, TGF-ß–treated PECs underwent proliferation; however, OT-I cells stimulated in this manner initiated incorporation of radioisotope within 48 hours (earlier than OT-I T cells stimulated by untreated PECs). Moreover, OT-I T cells exposed to TGF-ß2–treated PECs rapidly lost their proliferative capacity when assessed at 96 hours. These results reveal that OT-I T cells can be activated by both TGF-ß–treated and TGF-ß–untreated PECs but that the kinetics of the response are different. T cells responding to TGF-ß–treated PECs showed earlier proliferation followed by loss of this function, whereas conventionally stimulated T cells gradually displayed a sustained, proliferation phenotype.

View larger version (14K): [in this window] [in a new window]   Figure 1. Proliferative responses of OT-I T cells stimulated with TGF-ß2–pretreated PECs and various doses of OVA. PECs were cultured overnight with or without 5 ng/ml of TGF-ß2 and indicated concentrations of OVA, then washed, and cocultured with OT-I T cells. OT-I T cells were cultured with no PECs as negative control. T-cell proliferation responses were measured at 48, 72, and 96 hours. [3H]thymidine was added 8 hours before termination of culture. The experiment was repeated three times with similar results. Each data point represents the mean ± SD of triplicate cultures. *P < 0.05, **P < 0.01.

View larger version (14K): [in this window] [in a new window]   Figure 2. Secretion of cytokines by OT-I T cells stimulated with OVA-pulsed, TGF-ß2–treated PECs. PECs were cultured overnight with and without 5 ng/ml of TGF-ß2 and indicated concentrations of OVA, then washed and cocultured with OT-I T cells. After 24 hours, the culture supernatants were harvested and assayed for IFN-, IL-2, and TNF- by ELISA. The experiment was repeated four times with similar results. Each data point represents the mean ± SD of duplicate cultures. *P < 0.05, **P < 0.01.

View larger version (22K): [in this window] [in a new window]   Figure 3. Cytotoxic activity of naive and OT-I T cells after in vitro stimulation. OT-I T cells (5 x 105/well) were cocultured with or without OVA (400 µg/ml) and TGF-ß2 (5 ng/ml)–pretreated PECs (1 x 106/well) in 24-well plates for 0, 24, 48, and 96 hours. Effector-to–target cell ratio was 50:1. Viable cells were tested for their ability to lyse EG.7 cells during a 4-hour assay. The experiment was repeated four times with similar results. *P < 0.05.

View larger version (16K): [in this window] [in a new window]   Figure 4. Impairment of proliferative responses of OVA-primed T cells cocultured with X-irradiated OT-I T cells stimulated with OVA and TGF-ß2–pretreated PECs. OT-I T cells were stimulated with OVA-pulsed, TGF-ß2–pretreated PECs for 72 hours, then washed and exposed to X-irradiation (2000 R). For positive controls, OT-I T cells were X-irradiated after stimulation with OVA-pulsed PECs in the absence of TGF-ß2. PECs (1 x 105/well) were cultured overnight with 100 µg/ml of OVA, then washed and prepared as "stimulators" in a 96-well culture plate. In vitro–activated X-irradiated cells were added (2 x 104/well) as "regulators" to cell mixtures comprised of "responders" (T cells from B6 mice primed in vivo with OVA plus CFA, 3 x 105/well). X-irradiated T cells from naive B6 mice were used as regulators in negative controls. (A) T-cell proliferation responses were measured at 72 hours. [3H]thymidine was added 8 hours before termination of culture. (B) The culture supernatants after 24 hours were harvested and assayed for IFN- by ELISA. The experiment was repeated twice with similar results. Each data point represents the mean ± SD of triplicate cultures. **P < 0.05.

To determine whether OT-I T cells stimulated with OVA and TGF-ß2–pretreated PECs suppressed responder cell function in an antigen-specific manner, C57BL/6 mice were immunized with HSA plus CFA. One week later, T cells were obtained from these mice and used as responders in cultures similar in design to those described above. In particular, the experimental cultures contained HSA-pulsed PECs plus X-irradiated OT-I T cells that had been activated previously by in vitro exposure to OVA-pulsed, TGF-ß2–pretreated PECs. The results of this experiment are displayed in Figure 5 . "Regulator" OT-I T cells failed to inhibit the proliferation of HSA-primed T cells (Fig. 5A) , and they failed to prevent these T cells from producing IFN- when stimulated with OVA-pulsed APCs in vitro (Fig. 5B) . Once again, no IL-4 was detected in any culture supernatants (data not shown). We concluded that CD8⁺ OT-I T cells activated in vitro by TGF-ß2–pretreated PECs acquire regulatory properties that equip them to modulate the behavior of bystander T cells in an antigen-specific manner.

View larger version (18K): [in this window] [in a new window]   Figure 5. Specificity of impaired proliferative responses of HSA-primed T cells cocultured with X-irradiated OT-I T cells stimulated with OVA and TGF-ß2–pretreated PECs. Responder T cells were obtained from normal C57BL/6 mice immunized with HSA plus CFA 1 week previously. Regulator OT-I T cells were prepared by stimulation with OVA-pulsed, TGF-ß2–pretreated PECs for 72 hours, then washed and exposed to X-irradiation (2000 R). Regulator X-irradiated T cells for positive controls were stimulated with OVA-pulsed PECs in the absence of TGF-ß2. Stimulator PECs (1 x 105/well) were cultured overnight with 100 µg/ml of OVA and/or HSA, then washed and added to 96-well culture plates. In vitro–activated X-irradiated cells were added (2 x 104/well) as regulators to cell mixtures comprised of responders (3 x 105/well). X-irradiated T cells from naive B6 mice were used as regulators in negative controls. (A) T-cell proliferation responses were measured at 72 hours. [3H]thymidine was added 8 hours before termination of culture. *Indicates values not significantly different from each other or from negative control. (B) Culture supernatants were harvested at 24 hours and assayed for IFN- by ELISA. The experiment was repeated three times with similar results. Each data point represents the mean ± SD of triplicate cultures. Asterisks indicate activity not detected.

View larger version (38K): [in this window] [in a new window]   Figure 6. Inhibition of DH expression by OT-I T cells stimulated with OVA and TGF-ß2–pretreated PECs. Regulator cells, OVA-specific responder cells, and stimulator cells pulsed with OVA were prepared as described in the legend to Figure 5 . Mixtures containing regulators (1 x 105/injection), responders (5 x 105/injection), and stimulators (5 x 105/injection) were injected (10 µl) into the ear pinnae of normal B6 mice. T cells from naive B6 mice were used as responders in negative controls. Ear swelling responses at 24 hours were assessed and expressed as mean ± SEM (n = 5) and compared with positive control. Bars represent the mean ± SEM (n = 5) of ear measurements for typical experiment. Asterisks indicate values significantly less than positive controls, P < 0.05.

To explore the same issue in vivo, OT-I T cells were activated in vitro with OVA-pulsed, TGF-ß2–pretreated PECs and then used as regulators in a local adoptive transfer assay as described above. Neutralizing anti–TGF-ß2 antibodies were added to cell mixtures containing regulators, responders, and stimulators. Controls contained isotype control antibodies. The results of a representation experiment are presented in Figure 7 . Ear swelling responses were reduced when in vitro–activated OT-I T cells were present in the inoculum, whether anti–TGF-ß2 antibodies were present or not. We concluded that the ability of in vitro–activated OT-I T cells to regulate bystander T cells in vivo is not dependent on the generation of TGF-ß2.

View larger version (61K): [in this window] [in a new window]   Figure 7. Effect of anti–TGF-ß antibodies on inhibition of DH expression by OT-I T cells stimulated with OVA and TGF-ß2–pretreated PECs. Regulator cells, OVA-specific responder cells, and stimulator cells pulsed with OVA were prepared as described in the legend to Figure 5 . Mixtures containing regulators (1 x 105/injection), responders (5 x 105/injection), and stimulators (5 x 105/injection) were injected (10 µl) into the ear pinnae of normal B6 mice. Neutralizing anti–TGF-ß2 antibodies or nonspecific goat antibodies (100 µg/mouse) were mixed with the cells and injected into ear pinnae. T cells from naive B6 mice were used as responders in negative controls. Ear swelling responses at 24 hours were assessed and expressed as mean ± SEM (n = 5), and compared with positive control. Bars represent the mean ± SEM (n = 5) of ear measurements for typical experiment. Asterisks indicate values significantly less than positive controls, P < 0.01.

	Discussion

Top Abstract Introduction Methods Results Discussion References

Unfortunately, the apparent rarity of CD4⁺ and CD8⁺ regulatory T cells in spleens of mice with ACAID has precluded their direct isolation and purification. Alternative strategies to study these cells "at a distance" have met with only limited success. Kosiewicz et al.¹⁷ have reported that splenic T cells removed from mice that received intracameral injections of OVA 1 week previously failed to undergo detectable proliferation, or to secrete IL-2, IL-4, IL-10, or IFN- when stimulated in vitro with OVA. However, CD4⁺ T cells stimulated in this manner did secrete increased amounts of TGF-ß compared with controls that received an injection of OVA by the intravenous or subcutaneous routes.¹⁷ In related studies, Kosiewicz et al.,¹⁷ and D’Orazio et al.,^{18 19 20} have found OVA-specific T cells that resemble the Th2 phenotype in the spleens and lymph nodes of mice that first encounter OVA via the anterior chamber and then receive a subcutaneous immunization with OVA plus CFA. It is still unclear whether these putative Th2 cells are the direct result of the anterior chamber route of antigen injection, or whether this route of antigen injection primes T cells in a manner that promotes their differentiation into Th2 cells when subsequently stimulated with antigen plus adjuvant. In any event, it has not been possible to harvest responding cells of this type from mice with ACAID for further detailed analysis.

Until or unless we succeed in isolating regulatory T cells from living mice with ACAID, we are forced to turn to in vitro models that in one way or another resemble the ACAID response. Such an in vitro model is created when PECs are treated with TGF-ß in vitro and then pulsed with antigen.^{21 22 23 24} Cells of this type induce OVA-specific immune deviation when injected intravenously in naïve mice, a response that resembles ACAID in several parameters. In the present studies, we stimulated OT-I T cells with PECs exposed to TGF-ß2 and OVA in vitro and examined the T-cell responses thereafter. T cells of OT-I mice are relevant because (a) they recognize an OVA-derived peptide in the context of a class I molecule and (b) they are CD8⁺.^{8 25} Thus, they have the potential to become the efferent regulatory T cells found in mice with ACAID.

Our results confirm the value of this alternative approach to studying ACAID regulatory T cells. OT-I T cells were activated to proliferate promptly when exposed to OVA-pulsed, TGF-ß2–pretreated PECs. However, the functional properties of the responding T cells differed substantially from OT-I T cells activated by OVA-pulsed PECs that had not been treated with TGF-ß. The former cells secreted none of the cytokines we assayed (IFN-, IL-2, TNF-, IL-4, IL-10). In addition, they lost their capacity to lyse OVA-expressing target cells, a property constitutively displayed by naïve OT-I T cells. However, OT-I T cells activated in vitro by TGF-ß–treated PECs were not rendered nonfunctional. When added to cultures containing primed OVA-specific T cells plus OVA-pulsed APCs, they suppressed responder cell proliferation and cytokine production. When mixed with OVA-specific effector T cells and OVA and injected into ear pinnae of normal mice, they prevented the expression of DH. We concluded that by exposing naïve CD8⁺ T cells to antigen presented by TGF-ß–treated APCs we can generate regulatory T cells that resemble functionally the efferent regulatory T cells typically found in the spleens of mice with ACAID. Whether these cells are identical to the efferent suppressor cells found in ACAID remains to be determined.

The implication of our results extends well beyond this important conclusion. First, the loss of cytotoxic function by OT-I T cells activated in vitro by TGF-ß–treated PECs implies that the ability of these cells to suppress DH expression is not mediated by cytotoxicity directed at OVA-bearing APCs, a possibility we had originally considered. Second, the failure of OT-I T cells activated by TGF-ß–treated PECs to secrete enhanced amounts of TGF-ß, as well as the inability of anti–TGF-ß antibodies to reverse suppression of DH expression by these cells, indicates that TGF-ß is not directly responsible for the inhibition observed. This is somewhat surprising because we have recently found that DO11.10 T cells activated in vitro by OVA-pulsed, TGF-ß–pretreated APCs differentiate into regulatory T cells that suppress the expression of DH through their secretion of TGF-ß.⁷ Third, OT-I T cells stimulated with OVA-pulsed, TGF-ß–pretreated PECs failed to secrete detectable amounts of IL-4 and IL-10. This implies that under the conditions of in vitro activation, OT-I T cells do not differentiate in the direction of T2 cells. In this manner, OT-I T cells differ from DO11.10 T cells similarly activated. Based on reports of Takeuchi et al.¹⁰ and D’Orazio et al.,¹⁹ DO11.10 T cells differentiate into Th2-type cells when activated in vitro by TGF-ß–treated APCs. Taken together, these findings have enabled us to exclude several mechanisms postulated to account for the inhibitory activities of CD8⁺ OT-I T cell regulators. Unfortunately, positive identification of the operative mechanism remains to be achieved.

The specificity of the suppression mediated by in vitro–activated OT-I T cells is worthy of comment. OT-I T cells first exposed to OVA-pulsed, TGF-ß–pretreated PECs readily suppressed proliferation and IFN- secretion by T cells from mice primed with OVA in vivo. However, in vitro–activated T cells failed to suppress activation of T cells primed to HSA in vivo. The failure was even evident in cultures in which the APCs were pulsed with both HSA and OVA. It is pertinent that regulatory OT-I T cells neither secrete TGF-ß nor use TGF-ß in suppression of DH expression in vivo. The failure of in vitro–activated OT-I T cells to suppress T cells primed to irrelevant antigen is consistent with our interpretation that suppression by these cells is probably not dependent on the release of a soluble immunosuppressive factor.

Much has been learned about the effects of TGF-ß2 treatment on the antigen processing and presenting functions of APCs. Takeuchi et al. reported that PECs treated in this manner secrete reduced amounts of IL-12, upregulate CD40 expression poorly, and secrete increased amounts of mature TGF-ß compared with untreated PECs.²⁶ Circumstantial evidence has been presented to support the view that each of these effects contributes to the unusual phenotype of DO11.10 T cells that are exposed to OVA-pulsed, TGF-ß–treated PECs. It remains to be determined whether the unusual functional properties displayed by OT-I T cells exposed to OVA-pulsed, TGF-ß-treated PECs owe their origins to similar properties of the APC, or whether another set of TGF-ß–dependent properties is involved. Experiments to examine this issue are under way.

We are at a loss to explain the prompt, almost precocious, proliferation displayed by OT-I T cells exposed to OVA-pulsed, TGF-ß2–pretreated PECs. Nor do we know whether early proliferation followed by inability to proliferate is related to the regulatory properties displayed by these cells. At the very least the fact that regulatory cells emerge from these cultures indicates that early proliferation does not lead directly to apoptotic cell death.

	Acknowledgements

 
We thank Bruce Ksander, MD, for helpful suggestions and Jacqueline Doherty, MD, and Marie Ortega for managerial assistance.

	Footnotes

 
Supported by USPHS Grant EY 05678.

Submitted for publication September 27, 1999; revised December 20, 1999; accepted December 30, 1999.

Commercial relationships policy: N.

Corresponding author: J. Wayne Streilein, Schepens Eye Research Institute, 20 Staniford Street, Boston, MA 02114. waynes{at}vision.eri.harvard.edu

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Streilein, JW (1987) Immune regulation and the eye: a dangerous compromise FASEB J 1,199-208[Abstract]
2. Niederkorn, JY (1990) Immune privilege and immune regulation in the eye Adv Immunol 48,191-226[Medline][Order article via Infotrieve]
3. Streilein, JW (1997) Molecular basis of ACAID Ocular Immunol Inflamm 5,517-518
4. Streilein, JW, Ksander, BR, Taylor, AW (1997) Immune deviation in relation to ocular immune privilege J Immunol 158,3557-3560[Abstract]
5. Wilbanks, GA, Streilein, JW (1990) Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen: evidence of two functionally and phenotypically distinct T-suppressor cell populations Immunology 71,383-389[Medline][Order article via Infotrieve]
6. Wilbanks, GA, Mammolenti, M, Streilein, JW (1992) Studies on the induction of anterior chamber-associated immune deviation (ACAID), III: induction of ACAID depends upon intraocular transforming growth factor-beta Eur J Immunol 22,165-173[Medline][Order article via Infotrieve]
7. Kezuka T, Streilein JW. Analysis of in vivo regulatory properties of T cells activated in vitro by TGF-ß2–treated antigen presenting cells. Invest Ophthalmol Vis Sci. In press.
8. Hogquist, KA, Jameson, SC, Heath, WR, Howard, JL, Bevan, MJ, Carbone, FR (1994) T cell receptor antagonist peptides induce positive selection Cell 76,17-28[Medline][Order article via Infotrieve]
9. Taylor, AW, Alard, P, Yee, DG, Streilein, JW (1997) Aqueous humor induces transforming growth factor-beta (TGF-beta)-producing regulatory T-cells Curr Eye Res 16,900-908[Medline][Order article via Infotrieve]
10. Takeuchi, M, Kosiewicz, MM, Alard, P, Streilein, JW (1997) On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation Eur J Immunol 27,1648-1656[Medline][Order article via Infotrieve]
11. Moore, MW, Carbone, FR, Bevan, MJ (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation Cell 54,777-789[Medline][Order article via Infotrieve]
12. Williamson, JS, Streilein, JW (1988) Impaired induction of delayed hypersensitivity following anterior chamber inoculation of alloantigens Reg Immunol 1,15-23[Medline][Order article via Infotrieve]
13. Streilein, JW (1996) Peripheral tolerance induction: lessons from immune privileged sites and tissues Transplant Proc 28,2066-2070[Medline][Order article via Infotrieve]
14. Streilein, JW, Takeuchi, M, Taylor, AW (1997) Immune privilege, T-cell tolerance, and tissue-restricted autoimmunity Hum Immunol 52,138-143[Medline][Order article via Infotrieve]
15. Kosiewicz, MM, Okamoto, S, Miki, S, Ksander, BR, Shimizu, T, Streilein, JW (1994) Imposing deviant immunity on the presensitized state J Immunol 153,2962-2973[Abstract]
16. Kosiewicz, MM, Streilein, JW (1996) Intraocular injection of class II-restricted peptide induces an unexpected population of CD8 regulatory cells J Immunol 157,1905-1912[Abstract]
17. Kosiewicz, MM, Alard, P, Streilein, JW (1998) Alterations in cytokine production following intraocular injection of soluble protein antigen: impairment in IFN-gamma and induction of TGF-beta and IL-4 production J Immunol 161,5382-5390[Abstract/Free Full Text]
18. D’Orazio, TJ, Niederkorn, JY (1998) A novel role for TGF-beta and IL-10 in the induction of immune privilege J Immunol 160,2089-2098[Abstract/Free Full Text]
19. D’Orazio, TJ, Niederkorn, JY (1998) The nature of antigen in the eye has a profound effect on the cytokine milieu and resultant immune response Eur J Immunol 28,1544-1553[Medline][Order article via Infotrieve]
20. Li, XY, D’Orazio, LT, Niederkorn, JY (1996) Role of Th1 and Th2 cells in anterior chamber-associated immune deviation Immunology 89,34-45[Medline][Order article via Infotrieve]
21. Wilbanks, GA, Streilein, JW (1992) Macrophages capable of inducing anterior chamber associated immune deviation demonstrate spleen-seeking migratory properties Reg Immunol 4,130-137[Medline][Order article via Infotrieve]
22. Wilbanks, GA, Streilein, JW (1992) Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming growth factor-beta Eur J Immunol 22,1031-1036[Medline][Order article via Infotrieve]
23. Hara, Y, Caspi, RR, Wiggert, B, Dorf, M, Streilein, JW. (1992) Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye [published erratum appears in J Immunol. 1992;149(12):4116] J Immunol. 149,1531-1538[Abstract]
24. Hara, Y, Okamoto, S, Rouse, B, Streilein, JW (1993) Evidence that peritoneal exudate cells cultured with eye-derived fluids are the proximate antigen-presenting cells in immune deviation of the ocular type J Immunol 151,5162-5171[Abstract]
25. Kurts, C, Heath, WR, Carbone, FR, Allison, J, Miller, JF, Kosaka, H. (1996) Constitutive class I-restricted exogenous presentation of self antigens in vivo J Exp Med 184,923-930[Abstract/Free Full Text]
26. Takeuchi, M, Alard, P, Streilein, JW (1998) TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells J Immunol 160,1589-1597[Abstract/Free Full Text]

This article has been cited by other articles:

				R. E. Cone, S. Chattopadhyay, R. Sharafieh, Y. Lemire, J. O'Rourke, R. A. Flavell, and R. B. Clark T cell sensitivity to TGF-{beta} is required for the effector function but not the generation of splenic CD8+ regulatory T cells induced via the injection of antigen into the anterior chamber Int. Immunol., May 1, 2009; 21(5): 567 - 574. [Abstract] [Full Text] [PDF]

				J. A. Kapp, K. Honjo, L. M. Kapp, X. y. Xu, A. Cozier, and R. P. Bucy TCR transgenic CD8+ T cells activated in the presence of TGF{beta} express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection Int. Immunol., November 1, 2006; 18(11): 1549 - 1562. [Abstract] [Full Text] [PDF]

				S. Masli, B. Turpie, and J W. Streilein Thrombospondin orchestrates the tolerance-promoting properties of TGF{beta}-treated antigen-presenting cells Int. Immunol., May 1, 2006; 18(5): 689 - 699. [Abstract] [Full Text] [PDF]

				H. Keino, S. Masli, S. Sasaki, J. W. Streilein, and J. Stein-Streilein CD8+ T Regulatory Cells Use a Novel Genetic Program that Includes CD103 to Suppress Th1 Immunity in Eye-Derived Tolerance. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1533 - 1542. [Abstract] [Full Text] [PDF]

				T. Kezuka, M. Takeuchi, H. Keino, Y. Usui, A. Takeuchi, N. Yamakawa, and M. Usui Peritoneal Exudate Cells Treated with Calcitonin Gene-Related Peptide Suppress Murine Experimental Autoimmune Uveoretinitis via IL-10 J. Immunol., July 15, 2004; 173(2): 1454 - 1462. [Abstract] [Full Text] [PDF]

				J. Zhang-Hoover and J. Stein-Streilein Tolerogenic APC Generate CD8+ T Regulatory Cells That Modulate Pulmonary Interstitial Fibrosis J. Immunol., January 1, 2004; 172(1): 178 - 185. [Abstract] [Full Text] [PDF]

				J. W. Streilein Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation J. Leukoc. Biol., August 1, 2003; 74(2): 179 - 185. [Abstract] [Full Text] [PDF]

				K. C. McKenna, Y. Xu, and J. A. Kapp Injection of Soluble Antigen into the Anterior Chamber of the Eye Induces Expansion and Functional Unresponsiveness of Antigen-Specific CD8+ T Cells J. Immunol., November 15, 2002; 169(10): 5630 - 5637. [Abstract] [Full Text] [PDF]

				Y. Wang, I. Goldschneider, J. O’Rourke, and R. E. Cone Blood mononuclear cells induce regulatory NK T thymocytes in anterior chamber-associated immune deviation J. Leukoc. Biol., May 1, 2001; 69(5): 741 - 746. [Abstract] [Full Text]

				G. E. Plautz, S. Mukai, P. A. Cohen, and S. Shu Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors J. Immunol., October 1, 2000; 165(7): 3656 - 3662. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kezuka, T. Articles by Streilein, J. W. Search for Related Content PubMed PubMed Citation Articles by Kezuka, T. Articles by Streilein, J. W.